ClinicalTrials.gg
TerminatedNCT00774878Updated Mar 3, 2011

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

A Phase 2 interventional study of AVE1642 and Fulvestrant in Breast Neoplasms, sponsored by Sanofi. Terminated at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-03.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Breast Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Breast Neoplasms · Sanofi.

Enrollment
31st of 38
18 · median 79
Started
2008
with 1 other
Phase 2
21 of 40
none open now
Registered
22nd of 40
by date

Among the 40 studies in Breast Neoplasms by Sanofi, this one is the 31st largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2008, is one of 21 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 40 studies in Breast Neoplasms by Sanofi is open now. The open studies under Breast Neoplasms, anywhere →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies in Breast Neoplasms by Sanofi as a file.
02

Study summary

The purpose of this study is to evaluate the clinical activity of AVE1642 in combination with fulvestrant and of fulvestrant alone in terms of clinical benefit as the rate of "complete response", "partial response" and "stabilization of the disease".

The additional objectives are to evaluate the safety profile of AVE1642 in combination with fulvestrant and of fulvestrant alone, to assess the rate of patients without disease progression at 6 months and the overall progression-free survival time. An evaluation of the pharmacokinetics and pharmacodynamics interactions between AVE1642 and fulvestrant will also be performed.

The biological activity of treatment will be assessed on tumor biopsies, when possible The potential immunogenicity of AVE1642 will be studied

Read the detailed description

The study treatment will be administered until disease progression, unacceptable toxicity or patient willingness to discontinue.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • Breast cancer
  • Breast Tumors
  • Anti IGF-1R
  • Hormonosensitivity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • Aromatase inhibitor as the last hormonal treatment
  • Breast adenocarcinoma with positive hormone receptor
  • as per definition

Exclusion criteria

Exclusion Criteria:

  • performance status (PS) > 2
  • Prior exposure to fulvestrant or to an anti IGF-1R compound
  • No evidence of hormonosensitivity
  • HER 2-neu positive tumor
  • More than one prior regimen of chemotherapy for disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: AVE1642 · Drug: Fulvestrant

  • Active comparator
    Arm B

    Drug: Fulvestrant

Interventions

  • AVE1642 is administered intravenously at the dose of 8 mg/kg.

  • Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).

06

What researchers measure

Primary outcomes

  1. Clinical benefit defined as a confirmed complete response (CR) or a confirmed partial response (PR) or a stable disease (SD)lasting at least 24 weeks (6 cycles)

    Time frame: 6 cycles

Secondary outcomes

  1. Progression Free rate

    Time frame: at 6 months

  2. Safety (TEAEs, hematology, biochemistry parameters)

    Time frame: study period

07

Study locations

3 sites
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 17, 2008
Start
Oct 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Last update
Mar 3, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00774878
Lead sponsor
Sanofi
First posted
Oct 17, 2008
Start date
Oct 2008
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Mar 3, 2011

Study contacts

Henri ROCHE, Professor
principal investigator · Institut Claudius Regaud (TOULOUSE - FRANCE)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVE1642

Start the discussion